Viegas O A, Singh K, Adaikan P G, Karim S M, Ratnam S S
Prostaglandins Leukot Med. 1986 Jan;21(1):61-8. doi: 10.1016/0262-1746(86)90163-0.
Experience with a new sustained release PGE2 formulation is presented. 111 high risk primiparae with very poor cervical scores (less than 3) were studied. In 59 patients, labour was induced by forewater amniotomy and I.V. oxytocin. In the remaining 52 patients, film containing 850 ug of PGE2 was inserted into the vagina to ropen the cervix 24 hours prior to induction of labour. Indications for elective delivery and maternal characteristics were similar in both groups. There were significant changes in the cervical state within 12 hours of vaginal insertion. By 24 hours, 19 patients receiving vaginal film (36.5%) had established labour of whom 13 proceeded to vaginal delivery. Significantly fewer patients in the priming group required Caesarean delivery. No untoward maternal or fetal side effects were observed. Safety, ease of administration and efficacy make this new PGE2 formulation a useful agent for priming of the very poor primiparous cervix prior to induction of high risk labour.
本文介绍了一种新型前列腺素E2(PGE2)缓释制剂的应用经验。研究对象为111例宫颈评分极低(小于3分)的高危初产妇。59例患者采用人工破膜及静脉滴注缩宫素引产。其余52例患者在引产24小时前将含850微克PGE2的薄膜置入阴道以扩张宫颈。两组择期分娩的指征及产妇特征相似。阴道置入薄膜后12小时内宫颈状态有显著变化。到24小时时,接受阴道薄膜治疗的19例患者(36.5%)已发动分娩,其中13例经阴道分娩。预处理组行剖宫产的患者明显较少。未观察到产妇或胎儿的不良副作用。安全性、给药便捷性及有效性使这种新型PGE2制剂成为高危分娩引产术前扩张宫颈条件极差的初产妇的有效药物。